Morphological characteristic during third week experimental nephrolithiasis model

The results of kidney medulla morphological study from Wistar rats with ethylenglycol oxalate nephrolithiasis model are analyzed. Alteration of internal and external medulla, microliths allocation characteristics are evaluated

Preparation of Class Y Immunoglobulins that Neutralize the Marburg Virus

The aim was to study the possibility of inducing Marburg-neutralizing chicken antibodies (MARV) using various immunogens.Materials and methods. Recombinant vaccinia virus expressing the surface glycoprotein (GP) transgene MARV of Musoke strain and pseudovirus particles exhibiting GP of three strains of MARV – Popp, Musoke and DRC2000 based on lentivirus and recombinant strain of vesicular stomatitis virus (VSV) were used as immunogens. Two groups of birds were involved in the study. Chickens were immunized 9 times: first time they were injected with the recombinant vaccinia virus, and then 8 times – with pseudovirus particles (based on lentivirus and a recombinant strain of the vesicular stomatitis virus). The accumulation of specific antibodies was evaluated by enzyme-linked immunosorbent assay (ELISA). We used recombinant VSV exhibiting GP MARV, and natural MARV strain Popp for the analysis of accumulation of neutralizing antibodies.Results and discussion. We have developed an effective immunization schedule for chickens with three recombinant constructs presenting GP MARV, which results in the induction of chicken IgY antibodies against Marburg virus with a titer in ELISA from 1:100 to 1:1 million. The obtained IgY neutralize MARV pseudoviruses (Popp, DRC2000, Musoke) at a dilution of 1/256 to 1/1024 and the natural MARV virus of the Popp strain at a dilution of 1/8. More stable results were demonstrated by immunization using Freund’s incomplete adjuvant

ОПЫТ ПРИМЕНЕНИЯ ГИПОТЕРМИИ ВОЛОСИСТОЙ ЧАСТИ КОЖИ ГОЛОВЫ ДЛЯ ПРОФИЛАКТИКИ АЛОПЕЦИИ ПРИ ПРОВЕДЕНИИ ХИМИОТЕРАПИИ

Short-term results of using Orbis II Paxman device for prevention of chemotherapy-induced alopecia were analyzed. A total of 98 sessions of scalp cooling were performed in 32 patients.  Twenty-four (80 %) scalpcooled patients had good hair preservation. The level of comfort during the procedure was 87 %. Patients with breast cancer underwent 55 scalp cooling sessions.  Good hair preservation was observed in 88% of cases. Grade 1 and 2 alopecia was observed in 12% of patients.  Thus, the data obtained confirm that the use of scalp cooling methods can improve the quality of life for patients receiving chemotherapy.Представлены непосредственные результаты использования аппарата Orbis II Paxman для профилактики алопеции при проведении системной химиотерапии. Было проведено 98 сеансов локальной гипотермии волосистой части головы у 32 пациентов. У 24 человек (80 %) волосы сохранены в полном объеме. Уровень комфортности при проведении процедуры составил 87 %. Чаще всего гипотермия проводилась пациентам с диагнозом рак молочной железы – 55 сеансов. В 88 % случаев волосы сохранены в полном объеме, у 12 % отмечалась алопеция I и II степени. Использование методики охлаждения волосистой части кожи головы улучшает качество жизни пациентов

Сравнительная оценка эффективности иммуномодулирующей терапии при инфекционном мононуклеозе смешанной этиологии (Эпштейна – Барр и цитомегаловирусной) у детей

Objective: to conduct a comparative assessment of the effectiveness of immunomodulatory drugs in infectious mononucleosis of mixed etiology (EBV and CMV) in children, using the principles of evidence-based medicine.Materials and methods: a comprehensive comparative assessment of the effectiveness of immunomodulatory drugs in children with infectious mononucleosis EBV+CMV-etiology in 3 groups: group I-20 patients receiving recombinant interferon α-2β, group II-20 children receiving interferon – meglumin inducer acridonacetate and group III-20 children treated with a synthetic immunomodulator-inosin pranobex. The comparison group (IV) consisted of 20 children who received basic therapy.Results: Analysis of key intervention indicators for the outcome «fever Duration less than 5 days» showed the highest effectiveness of recombinant interferon α-2β, less effective were meglumina  acridonacetate and inosine pranobex. According to the outcomes «Reduction of lymph nodes by 2 or more times» and «Reduction of the liver and spleen by 2 or more times», data on the advantage of meglumin acridonacetate were obtained. The recombinant interferon α-2β was the second most effective. All the studied drugs do notsignificantly affect the severity of the hematological syndrome. The expediency of using immunomodulatory therapy in infectious mononucleosis of EBV+CMV-etiology is shown, the deviation from the norm of the integral outcome indicator is significantly higher in the group of children who were on symptomatic therapy. The overall effectiveness of the studied immunomodulatory drugs with all clinical outcomes does not have statistically significant differences.Conclusion: the obtained data allow us to rationally approach the choice of immunomodulatory therapy, taking into account the effectiveness of clinical outcomes and the overall effectiveness of the drug.Цель: провести сравнительную оценку эффективности иммуномодулирующих препаратов при инфекционном мононуклеозе смешанной этиологии (Эпштейна – Барр и цитомегаловирусной) у детей, используя принципы доказательной медицины.Материалы и методы: проведена комплексная сравнительная оценка эффективности иммуномодулирующих препаратов у детей с инфекционным мононуклеозом смешанной этиологии (Эпштейна – Барр и цитомегаловирусной) в 3 группах детей, которые на фоне базисной терапии (патогенетической и симптоматической) получали иммуномодуляторы: I группа – 20 пациентов, получавших рекомбинантный интерферон α-2β, II группа – 20 детей, получавших индуктор интерферона – меглюмина акридонацетат, и III группа – 20 детей, лечившихся синтетическим иммуномодулятором – инозином пранобексом. Группу сравнения (IV) составили 20 детей, получавших только базисную терапию.Результаты: анализ ключевых показателей вмешательства по исходу «Длительность лихорадки менее 5 дней» показал наибольшую эффективность рекомбинантного интерферона α-2β, менее эффективными были меглюмина акридонацетат и инозин пранобекс. По исходам «Сокращение лимфатических узлов в 2 и более раз» и «Сокращение печени и селезенки в 2 и более раз» получены данные о преимуществе меглюмина акридонацетата. На втором месте по эффективности оказался рекомбинантный интерферона α-2β. Все исследованные препараты не оказывают существенного влияния на выраженность гематологического синдрома. Показана целесообразность применения иммуномодулирующей терапии при инфекционном мононуклеозе смешанной этиологии (Эпштейна – Барр и цитомегаловирусной), отклонение от нормы интегрального показателя исхода значимо выше в группе детей, которые находились на симптоматической терапии. Общая эффективность исследуемых иммуномодулирующих препаратов при всех клинических исходах не имеет статистически значимых различий.Заключение: полученные данные позволяют рационально подойти к выбору иммуномодулирующей терапии с учетом эффективности по клиническим исходам и общей эффективности препарата

Clinical and virological characteristics of acute respiratory infections (ARI) with lesions of the larynx in children

The article analyzes the etiological structure of the pathogens and clinical presentation of ARI with lesions of the larynx in children treated in the infectious box at the Samara City Children's Clinical Hospital No.1 named after N.N. Ivanova in the period from 2010 to 2015

EXPERIENCE OF SCALP COOLING FOR PREVENTION CHEMOTHERAPY-INDUCED HAIR LOSS

Short-term results of using Orbis II Paxman device for prevention of chemotherapy-induced alopecia were analyzed. A total of 98 sessions of scalp cooling were performed in 32 patients.  Twenty-four (80 %) scalpcooled patients had good hair preservation. The level of comfort during the procedure was 87 %. Patients with breast cancer underwent 55 scalp cooling sessions.  Good hair preservation was observed in 88% of cases. Grade 1 and 2 alopecia was observed in 12% of patients.  Thus, the data obtained confirm that the use of scalp cooling methods can improve the quality of life for patients receiving chemotherapy

Comparative evaluation of the effectiveness of immunomodulatory therapy for infectious mononucleosis of mixed etiology (Epstein Barr and cytomegalovirus) in children

Objective: to conduct a comparative assessment of the effectiveness of immunomodulatory drugs in infectious mononucleosis of mixed etiology (EBV and CMV) in children, using the principles of evidence-based medicine.Materials and methods: a comprehensive comparative assessment of the effectiveness of immunomodulatory drugs in children with infectious mononucleosis EBV+CMV-etiology in 3 groups: group I-20 patients receiving recombinant interferon α-2β, group II-20 children receiving interferon – meglumin inducer acridonacetate and group III-20 children treated with a synthetic immunomodulator-inosin pranobex. The comparison group (IV) consisted of 20 children who received basic therapy.Results: Analysis of key intervention indicators for the outcome «fever Duration less than 5 days» showed the highest effectiveness of recombinant interferon α-2β, less effective were meglumina  acridonacetate and inosine pranobex. According to the outcomes «Reduction of lymph nodes by 2 or more times» and «Reduction of the liver and spleen by 2 or more times», data on the advantage of meglumin acridonacetate were obtained. The recombinant interferon α-2β was the second most effective. All the studied drugs do notsignificantly affect the severity of the hematological syndrome. The expediency of using immunomodulatory therapy in infectious mononucleosis of EBV+CMV-etiology is shown, the deviation from the norm of the integral outcome indicator is significantly higher in the group of children who were on symptomatic therapy. The overall effectiveness of the studied immunomodulatory drugs with all clinical outcomes does not have statistically significant differences.Conclusion: the obtained data allow us to rationally approach the choice of immunomodulatory therapy, taking into account the effectiveness of clinical outcomes and the overall effectiveness of the drug